Plasminogen (Plg) activator inhibitor-1 (PAI-1) is an important fibrosis-promoting molecule. Whether this effect can be attributed to PAI-1's activity as an inhibitor of plasmin generation is debated. This study was designed to investigate the role of Plg in renal fibrosis using in vivo and in vitro approaches. Plg-deficient (Plg-/-) and wild-type (Plg+/+) C57BL/6 mice were subjected to unilateral ureteral obstruction or sham surgery (n = 8/group; sham, days 3, 7, 14, and 21). Plg deficiency was confirmed by the absence of Plg mRNA, protein, and plasmin activity. After 21 d of unilateral ureteral obstruction, total kidney collagen was significantly reduced by 35% in the Plg-/- mice. Epithelial-to-mesenchymal transition (EMT), as typified by tubular loss of E-cadherin and acquisition of alpha-smooth muscle actin, was also significantly reduced in Plg-/- mice, 76% and 50%, respectively. Attenuation of EMT and fibrosis severity in the Plg-/- mice was associated with significantly lower levels of phosphorylated extracellular signal-regulated kinase (ERK) and active TGF-beta. In vitro, addition of plasmin (20 microg/ml) to cultures of murine tubular epithelial cells initiated ERK phosphorylation within minutes, followed by phenotypic transition to fibroblast-specific protein-1+, alpha-smooth muscle actin+, fibronectin-producing fibroblast-like cells. Both plasmin-induced ERK activation and EMT were significantly blocked in vitro by the protease-activated receptor-1 (PAR-1) silencing RNA; by pepducin, a specific anti-PAR-1 signaling peptide; and by the ERK kinase inhibitor UO126. Plasmin-induced ERK phosphorylation was enhanced in PAR-1-overexpressing tubular cells. These findings support important profibrotic roles for plasmin that include PAR-1-dependent ERK signaling and EMT induction.

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2006080886DOI Listing

Publication Analysis

Top Keywords

plg-/- mice
12
epithelial-to-mesenchymal transition
8
unilateral ureteral
8
ureteral obstruction
8
alpha-smooth muscle
8
erk phosphorylation
8
plasmin-induced erk
8
erk
6
plasminogen promotes
4
promotes renal
4

Similar Publications

We developed a novel adeno-associated virus 5 gene therapy (AAV5-GLA) expressing human alpha-galactosidase A (GLA) under the control of a novel, small and strong, liver-restricted promoter. We assessed the preclinical potential of AAV5-GLA for treating Fabry disease, an X-linked hereditary metabolic disorder resulting from mutations in the gene encoding GLA that lead to accumulation of the substrates globotriaosylceramide and globotriaosylsphingosine, causing heart, kidney, and central nervous system dysfunction. Effects of intravenously administered AAV5-GLA were evaluated in (1) GLA-knockout mice aged 7-8 weeks (early in disease) and 20 weeks (nociception phenotype manifestation) and (2) cynomolgus macaques during an 8-week period.

View Article and Find Full Text PDF

A Modular Approach to Obtain HER2-Targeting DM1-Loaded Nanoparticles for Gastric Cancer Therapy.

ACS Omega

December 2024

Gastroenteric Medicine and Digestive Endoscopy Center, The Second Hospital of Jilin University, Changchun, Jilin Province 130041, China.

Article Synopsis
  • Antibody-based tumor-targeting nanomedicines face challenges in preparation and storage, prompting a new synthesis method for durable, ready-to-use drugs.
  • The research focuses on creating HER2-targeting DM1-loaded nanoparticles for treating gastric cancer using a modular approach, achieving high drug loading and HER2 targeting.
  • The developed nanoparticles show significant cytotoxicity against gastric cancer cells, rapid tumor accumulation, and effective tumor growth inhibition in mice, while minimizing toxicity to the liver and kidneys.
View Article and Find Full Text PDF

Dual Opdivo plus Yervoy immunotherapy, targeting the immune checkpoints PD1 and CTLA-4, is successful in clinical use. However, it is associated with a high incidence of adverse events, and its therapeutic efficacy needs improving. In this study, polymeric multivalent Fc-binding peptides (PLG-Fc-III-4C) are employed to fabricate a bispecific antibody (PD1/CTLA-4 BsAb) to potentiate dual immunotherapy targeting PD1 and CTLA-4.

View Article and Find Full Text PDF

Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice.

J Thromb Haemost

October 2024

Cardeza Foundation for Hematologic Research, Department of Medicine, Division of Hematology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address:

Background: Phosphatidylserine (PS) is a procoagulant phospholipid enriched on surfaces of activated vascular cells including platelets, endothelium, monocytes, and microvesicles. As a molecular driver of thrombosis accessible to drug blockade, PS is an attractive pharmacologic target for modulating thrombogenesis, with potentially reduced bleeding risk compared to anticoagulant and antiplatelet therapies.

Objectives: Test antithrombotic capabilities of a liposomal formulation, Zn-dipicolylamine cyanine-3[22,22]/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (molar ratio, 3:97), designated as DPAL, which we previously described binds selectively to PS-enriched cell surfaces, compared with effects on bleeding, in mouse models.

View Article and Find Full Text PDF

A microparticle delivery system for extended release of all-trans retinoic acid and its impact on macrophage insulin-like growth factor 1 release and myotube formation.

Int J Pharm

December 2024

Biomedical Engineering Program, University of South Carolina, Columbia, SC 29208, USA; Department of Chemical Engineering, University of South Carolina, Columbia, SC 29208, USA; Veterans Affairs Medical Center, Columbia, SC 29209, USA. Electronic address:

Article Synopsis
  • - Muscle atrophy due to disuse, aging, or illness can lead to increased risks of injury and prolonged recovery, with macrophages playing a crucial role in muscle regeneration by releasing insulin-like growth factor 1 (IGF-1).
  • - Researchers encapsulated all-trans retinoic acid (ATRA) in microparticles to improve its bioavailability and promote IGF-1 release from macrophages, enhancing muscle cell formation and regeneration.
  • - The study shows that ATRA-PLG microparticles are effectively taken up by macrophages and can stimulate IGF-1 production, supporting further research on its potential use in muscle recovery treatments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!